[HTML][HTML] Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma
RL Piekarz, R Frye, M Turner, JJ Wright… - Journal of clinical …, 2009 - ncbi.nlm.nih.gov
Journal of clinical oncology, 2009•ncbi.nlm.nih.gov
Purpose Romidepsin (depsipeptide or FK228) is a member of a new class of antineoplastic
agents active in T-cell lymphoma, the histone deacetylase inhibitors. On the basis of
observed responses in a phase I trial, a phase II trial of romidepsin in patients with T-cell
lymphoma was initiated.
agents active in T-cell lymphoma, the histone deacetylase inhibitors. On the basis of
observed responses in a phase I trial, a phase II trial of romidepsin in patients with T-cell
lymphoma was initiated.
Abstract
Purpose
Romidepsin (depsipeptide or FK228) is a member of a new class of antineoplastic agents active in T-cell lymphoma, the histone deacetylase inhibitors. On the basis of observed responses in a phase I trial, a phase II trial of romidepsin in patients with T-cell lymphoma was initiated.
ncbi.nlm.nih.gov